Last $26.27 USD
Change Today +0.22 / 0.84%
Volume 1.4M
IPXL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

impax laboratories inc (IPXL) Key Developments

Impax Laboratories Inc. Appoints G. Frederick Wilkinson as President and Chief Executive Officer, Effective April 29, 2014

Impax Laboratories Inc. announced that its Board of Directors has appointed G. Frederick Wilkinson as company's President and Chief Executive Officer effective April 29, 2014. Mr. Wilkinson, who previously served as President, Actavis Global Research and Development at Actavis plc succeeds Larry Hsu, Ph.D. who is retiring. Mr. Wilkinson, 57, joined Watson Pharmaceuticals Inc. (now Actavis) as Executive Vice President, Global Brands in September 2009. Prior to joining Watson, he was President and Chief Operating Officer of Duramed Pharmaceuticals Inc.

Impax Laboratories Inc. Announces Executive Changes

Impax Laboratories Inc. appointed Jeffrey Nornhold as senior vice president of technical operations and will oversee the company's manufacturing, supply chain, quality and technical operations. Mr. Nornhold previously served as the company's Senior vice president, Global Quality Affairs since March 2011. Mark Fitch, Senior vice president, Global Operations announced his plans to retire, but will continue to work with Nornhold to ensure a smooth transition.

Impax Launches Authorized Generic RENVELA(R)

Impax Laboratories Inc. announced that it is commencing shipment of authorized generic RENVELA (sevelamer carbonate 800 mg tablets), through Global Pharmaceuticals, Impax's generics division. RENVELA is indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis. Under the terms of a settlement agreement, Genzyme agreed to grant Impax a license to sell an allotment of a specified number of bottles of an authorized generic version of RENVELA tablets commencing on April 16, 2014. Impax continues to pursue approval of its pending Abbreviated New Drug Application for generic RENVELA with the U.S. Food and Drug Administration (FDA).

Impax Pharmaceuticals Announces Resubmission of New Drug Application forRYTARY(TM) (Carbidopa and Levodopa) xtended-Release Capsules (IPX066)

Impax Pharmaceuticals announced the resubmission of Impax's New Drug Application (NDA) for RYTARY (IPX066) to the U.S. Food and Drug Administration (FDA). IPX066 is a patented extended- release capsule formulation of carbidopa and levodopa, an investigational drug for the symptomatic treatment of Parkinson's disease (PD). After discussions with the FDA, the Company has resubmitted the NDA for RYTARY providing updated safety and stability information. The FDA will require an inspection of manufacturing facilities involved in the production of RYTARY in connection with the resubmission. The FDA has designated the NDA filing for RYTARY as a Class 2 resubmission for review purposes and has 14 calendar days to officially accept the NDA resubmission. RYTARY is an investigational extended-release capsule formulation of carbidopa and levodopa for the treatment of idiopathic Parkinson's disease.

Impax Laboratories Inc. Announces Executive Changes

Impax Laboratories Inc. announced that Jeffrey D. Nornhold has been appointed Senior Vice President, Technical Operations and will oversee the Company's manufacturing, supply chain, quality and technical operations. Mr. Nornhold previously served as the company's Senior Vice President, Global Quality Affairs since March 2011. Mark Fitch, Senior Vice President, Global Operations announced his plans to retire, but will continue to work with Nornhold to ensure a smooth transition.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IPXL:US $26.27 USD +0.22

IPXL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $24.04 USD -0.61
BTG PLC 549.50 GBp -2.00
Glenmark Pharmaceuticals Ltd 570.20 INR -5.90
Lannett Co Inc $34.67 USD -1.18
OraSure Technologies Inc $6.89 USD -0.23
View Industry Companies
 

Industry Analysis

IPXL

Industry Average

Valuation IPXL Industry Range
Price/Earnings 17.7x
Price/Sales 3.4x
Price/Book 2.2x
Price/Cash Flow 18.0x
TEV/Sales 2.8x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMPAX LABORATORIES INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.